

Management of familial heterozygous hypercholesterolemia

Position paper of the Polish Lipid Expert Forum

Andrzej Rynkiewicz¹, Barbara Cybulska², Maciej Banach³, Krzysztof J. Filipiak⁴, Tomasz Guzik⁵, Barbara Idzior-Walus⁶, Jacek Imiela⁷, Piotr Jankowski⁸, Longina Kłosiewicz-Latoszek^{2,9,10}, Janusz Limon¹¹, Małgorzata Myśliwiec¹², Grzegorz Opolski¹³, **Andrzej Steciwko**¹⁴, Janina Stępińska¹⁵, Tomasz Zdrojewski¹⁶

1 1st Department of Cardiology, Medical University of Gdańsk, Gdańsk, Poland

2 Polish National Food and Nutrition Institute, Warszawa, Poland

3 Department of Nephrology and Arterial Hypertension, Medical University of Lodz, Łódź, Poland

4 1st Department of Cardiology, Warsaw Medical University, Warszawa, Poland

5 Department of Internal Diseases and Rural Medicine, Jagiellonian University Medical College, Kraków, Poland

6 Department of Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland

7 1st Department of Internal Diseases and Nephrology, Międzyzlesie Specialist Hospital, Warszawa, Poland

8 1st Department of Cardiology and Arterial Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

9 Polish National Food and Nutrition Institute, Warszawa, Poland

10 Department of Social Medicine and Hygiene, Warsaw Medical University, Warszawa, Poland

11 Department of Biology and Genetics, Medical University of Gdańsk, Gdańsk, Poland

12 Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdańsk, Gdańsk, Poland

13 1st Department of Cardiology, Warsaw Medical University, Warszawa, Poland

14 Department of Family Medicine, Wrocław Medical University, Wrocław, Poland

15 Department of Intensive Cardiac Care, National Institute of Cardiology, Warszawa, Poland

16 Unit of Prevention and Didactics, Department of Arterial Hypertension and Diabetology Medical University of Gdańsk, Gdańsk, Poland

Introduction Familial hypercholesterolemia (FH) is one of the better-known genetically determined diseases causing an accelerated development of atherosclerosis and early occurrence of cardiovascular events.¹⁻³ Symptoms of coronary heart disease develop in more than half of men with heterozygous FH (HeFH) before the age of 50 years and in 30% of women before the age of 60 years. Cardiovascular mortality in individuals with FH between 20 and 39 years of age is 100-times higher than in the general population.¹ Early identification of individuals with HeFH and effective pharmacotherapy may decrease the incidence of cardiovascular events and reduce premature mortality.^{4,5} Unfortunately, the majority of patients affected by HeFH in Poland are unaware of the disease.

Epidemiology and pathogenesis FH is the most common monogenetic disease.^{1,6} Due to the autosomal dominant inheritance, there are heterozygous (HeFH) and homozygous (HoFH) forms of

the disease. HoFH occurs in 1 per 1 million live births, while HeFH affects on average 1 in 500 individuals in the European countries.¹ It is estimated that HeFH in Poland may affect more than 80,000 people.

The phenotype of FH is associated with the mutation of 1 of the 3 genes: low-density lipoprotein (LDL) receptor gene (approx. 1600 different mutations were described), apolipoprotein B (*apoB*) gene or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) gene.⁷⁻¹⁰ Abnormal structure of LDL receptors or *apoB*, the ligand for LDL receptors, disturbs the binding of *apoB* containing lipoproteins to receptors. This results in impaired catabolism of LDL in the liver.^{11,12} In HeFH, the defect affects half the LDL receptors or half the *apoB* molecules. The third, recently discovered cause of FH is the presence of *PCSK9* gene mutation, which is associated with the degradation activity of LDL receptors by this protein (gain-of-function mutation).^{10,13}

Correspondence to:

Prof. Barbara Cybulska, MD, PhD,
Instytut Żywności i Żywienia
im. prof. dra med. Aleksandra
Szczygła, ul. Powiśńska 61/63,
02-903 Warszawa, Poland,
phone/fax: +48-22-842-49-47,
e-mail: barbara.cybulska@wp.pl

Received: December 10, 2012.

Accepted: December 11, 2012.

Conflict of interest: see pages 9-10.

Pol Arch Med Wewn. 2013;

123 (1-2): 7-10

Copyright by Medycyna Praktyczna,

Kraków 2013

Familial hypercholesterolemia as a risk factor for coronary heart disease

FH is a potent risk factor of coronary heart disease.¹⁴ The coexistence of additional risk factors, especially smoking, significantly accelerates the development of premature atherosclerosis.^{1,3} It is estimated that in the majority of untreated men and women with HeFH, coronary heart disease manifests itself before the age of 60 years. FH patients are a priori assigned to the high-risk group without the need to use the European Society of Cardiology (ESC) Heart Score or Framingham algorithm to estimate the cardiovascular risk in the primary prevention. Early implemented intensive pharmacotherapy before the appearance of atherosclerosis symptoms allows to achieve life expectancy among the individuals with HeFH similar to the general population.¹⁵⁻¹⁷

Heterozygous familial hypercholesterolemia diagnostic criteria

FH is diagnosed on the basis of the Dutch Lipid Network criteria adopted in Geneva in 1998 by the World Health Organization.¹ The criteria were also adopted by the ESC and European Atherosclerosis Society (EAS) in "ESC/EAS Guidelines for the Management of Dyslipidaemias" 2011.³ The clinical criteria of FH include high plasma levels of LDL cholesterol, presence of arcus cornealis and tendinous xanthomas, premature cardiovascular disease, and positive family history of hypercholesterolemia and premature cardiovascular disease.^{6,18,19} The presence of xanthomas on the extensor tendons of the hands and on the Achilles tendon is pathognomonic for the diagnosis of FH. The lower age limit for premature cardiovascular disease is considered to be 55 years in men and 60 years in women.

The basic biochemical parameter in FH diagnosis is the high level of LDL cholesterol (in heterozygotes usually from 2 to 3 times higher than the population average), usually with a normal level of triglycerides.^{1,16} Total cholesterol level in heterozygotes is usually between 290 and 500 mg/dl (7.5–12.9 mmol/l), and in homozygotes between 600 and 1000 mg/dl (15.5–25.8 mmol/l).¹ Lipid profile in patients with FH may resemble that obtained in secondary hypercholesterolemia, e.g., in the course of hypothyroidism, diabetes, nephrotic syndrome, as a result of long-term therapy with corticosteroids, progestogens, or protease inhibitors used to treat human immunodeficiency virus infection.³ Sometimes, an increased level of triglycerides secondary to, for example, diabetes, obesity, or excessive alcohol consumption occurs in typical FH. In such cases, any doubts about the diagnosis of FH can be clarified by obtaining a lipid profile of relatives and by genetic testing.¹⁹

The Dutch Lipid Network and Simon Broome Register criteria adapted to Polish conditions (TABLE) may be helpful in the office setting. They allow to make a certain, probable, or possible diagnosis of FH in the clinical setting.¹⁻³ It should be noted that the clinical diagnosis of FH might

be established without genetic testing.¹⁹ If financially feasible, it is advisable to confirm FH diagnosis by genetic methods, especially in doubtful cases.

Adapted Dutch Lipid Clinic Network and Simon Broome Register diagnostic criteria for HeFH are presented in the TABLE.

Recommendations for identification of heterozygous familial hypercholesterolemia

According to the National Institute for Health and Clinical Excellence (NICE) guidelines, coexistence of cholesterol concentration over 300 mg/dl (7.8 mmol/l) with premature cardiovascular disease in first-degree relatives (siblings, parents, or children) is strongly suggestive of FH.^{2,20} In families with FH, the condition should be diagnosed in children and dietetic treatment initiated as soon as possible; treatment with statins should be introduced in children over 10 years of age.²¹ If HeFH is diagnosed, cascade screening of the family is recommended, including both serum lipid profile and genetic testing (if possible).^{1,2,22}

The measurement of serum lipid concentration in children in families with FH is recommended even immediately after birth and always under 10 years of age. Children in such families should undergo periodic medical examinations, including the measurement of body weight and blood pressure.²¹

Atherosclerosis in FH develops insidiously and may be advanced before any signs or symptoms are noted. Markers of coronary heart disease may be present in asymptomatic patients.²³ Specialist care for patients with FH makes it possible to confirm the diagnosis of FH in dubious cases using a genetic method, introduce cascade testing in the families, and recommend lifestyle modifications and pharmacotherapy.^{22,24,25} It is necessary to provide patients with a quick access to diagnostic tests, which allows to detect significant cardiovascular disease and, if possible, cooperate with clinical geneticist. National programs for patients with FH are in place worldwide: MEDPED in the United States, StOEh in the Netherlands, HEART UK – The Nation's Cholesterol Charity in England, Fundacion Colesterol Familiar in Spain, Krajowe Centrum Diagnostyki Hipercholesterolemii Rodzinnej (National Centre for Diagnostics of Familial Hypercholesterolaemia) in Poland, and others. It must be stressed that there are no separate lipid clinics in the Polish health-care system.

Target low-density lipoprotein cholesterol concentration

After clinical diagnosis of FH has been established (a score of 5 or more), intensive treatment should be initiated without waiting for the results of molecular testing.²⁻⁵

The target LDL cholesterol concentration in patients with FH in primary prevention of coronary heart disease, due to a high risk, should be less than 2.5 mmol/l (<100 mg/dl). In patients with

TABLE Heterozygous familial hypercholesterolemia diagnostic criteria – score; adaptation of the Dutch Lipid Clinic Network (World Health Organization) and Simon Broome Register scale

clinical history		
premature coronary heart disease (men <55 years, women <60 years)		2
premature cerebral or peripheral vascular disease		1
family history		
first-degree relatives with premature coronary or vascular disease		1
first-degree relatives with LDL above 190 mg/dl		1
first-degree relatives with tendon xanthomata and/or corneal arcus		2
children aged less than 18 years with LDL cholesterol above 155 mg/dl		2
physical examination		
tendon xanthomata		6
corneal arcus below the age of 45 years		4
laboratory analysis		
LDL cholesterol	>8.5 mmol/l (330 mg/dl)	8
	6.5–8.4 mmol/l (250–329 mg/dl)	5
	5.0–6.4 mmol/l (190–249 mg/dl)	3
	4.0–4.9 mmol/l (155–189 mg/dl)	1
genetic testing		
mutation of LDL receptor gene		8
diagnosis of familial hypercholesterolemia		
definite		>8
probable		6–8
possible		3–5
no diagnosis		<3

Abbreviations: LDL – low-density lipoprotein

concomitant cardiovascular disease the risk is very high and the goal of treatment is LDL cholesterol concentration below 1.8 mmol/l (< 70 mg/dl).^{2,5} If this is not possible, reduction by at least 50% from baseline is recommended. This goal may be difficult to achieve with statins alone; therefore, combination pharmacotherapy is often necessary.³ In the ESC/EAS guidelines on the management of dyslipidemia (2011) the experts stated: “if the target level is not reached, statin combination with cholesterol absorption inhibitor or bile acid sequestrant or nicotinic acid may be considered”. In Poland, only the first option is currently feasible, i.e., the addition of ezetimibe after an attempt at treatment with the maximum tolerated dose of a statin, is feasible.

In our opinion, a score of 5 or more should be considered sufficient justification for the introduction of the recommended treatment of FH, reimbursed from the public means in Poland.

Therapeutic management of heterozygous familial hypercholesterolemia The most important objective of treatment in patients with FH is to reduce premature cardiovascular mortality as well as the incidence of myocardial infarction and the need for revascularization. Lifestyle changes are necessary to eliminate additional cardiovascular risk factors.³ Recommendations for patients with FH include absolute abstinence from

smoking, physical activity (at least 30 minutes of exercise for a minimum of 5 days per week – brisk walking, running, or cycling), arterial blood pressure <140/90 mmHg, body mass index <25 kg/m², avoidance (or treatment) of central obesity, and cholesterol-lowering diet.^{1–3} However, in patients with FH even an appropriate diet would not adequately lower the LDL cholesterol concentration, and the introduction of pharmacological treatment is necessary. In FH, the treatment of choice are statins at the maximum tolerated dose.^{3,18} Response to treatment with statins is highly individually variable (concentration reduction by 10% to 70%) due to (among other factors) the type of the LDL receptor mutation. Although statins are currently the most potent class of hypolipemic medications available, in many patients with FH (as mentioned above) the target LDL cholesterol concentrations cannot be achieved with monotherapy.^{2,3,18,25} In such cases, the goal of treatment should be the maximum LDL cholesterol reduction attainable with an appropriate combination treatment at tolerated doses: a statin with a cholesterol absorption inhibitor (ezetimibe), a bile acid-binding agent (anion-exchange resin), or nicotinic acid.³ In the case of statin intolerance, ezetimibe, an anion-exchange resin or nicotinic acid may be used in monotherapy. A modern anion-exchange resin (colesevelam) and nicotinic acid are not yet available in Poland. The position concerning treatment of children and adolescents will be presented in a separate paper.

Women with FH who plan pregnancy or are pregnant or breastfeeding should not receive statins.²⁶ In women of childbearing potential, the use of highly effective contraceptive methods is recommended; oral hormonal contraceptives should be avoided, if possible. Women should be instructed to stop hypolipemic treatment 3 months prior to the planned pregnancy.²⁶ The only hypolipemic treatment admissible in pregnancy is the use of an agent preventing the enterohepatic recirculation of bile acids (e.g., colesevelam).

A new class of medications, PCSK9 inhibitors, may offer a promising treatment option in FH, and the results of studies concerning these drugs (published in 2012) indicated that the hypolipemic effect of the investigated monoclonal antibodies was convincing.^{27–32}

Conclusions HeFH is a relatively common lipid disorder, usually remaining undiagnosed and untreated. A very high risk of cardiovascular diseases and a shortened lifespan in patients with this condition require early diagnosis and intensive treatment.

Note The position paper has been officially endorsed by the Cardiovascular Working Group of the Polish Cardiac Society.

Conflict of interest K.J.F.: honoraria for lectures/membership in advisory boards (Adamed, Astra-Zeneca, BerlinChemie, Bristol-Myers Squibb, Egis,

Krka, MSD, Novartis, Pfizer, Polpharma, Teva); T.G.: honoraria (Bayer); P.J.: honoraria for lectures/travel funds (Abbot, Adamed, AstraZeneca, MSD, Polpharma, Sanofi-Aventis, Zentiva); G.O.: clinical trials/lectures (Adamed, AstraZeneca, Egis, Krka, MSD, Novartis, Pfizer, Polpharma, Teva); J.S.: honoraria for lectures/membership in advisory boards (Adamed, AstraZeneca, Bristol-Myers Squibb, Egis, MSD, Novartis, Pfizer, Polpharma).

REFERENCES

- 1 Familial Hypercholesterolemia. A Report of a WHO consultation. WHO, Geneva, Switzerland, 1998.
- 2 Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. *BMJ*. 2008; 337: a1095.
- 3 European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2011; 32: 1769-1818.
- 4 Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous hypercholesterolemia: a prospective registry study. *Eur Heart J*. 2008; 29: 2625-2633.
- 5 Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolemia: a missed opportunity in preventive medicine. *Nat Clin Pract Cardiovasc Med*. 2007; 4: 404-405.
- 6 Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis*. 2004; 173: 55-68.
- 7 Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. *Sci Am*. 1984; 251: 52-60.
- 8 Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. *Proc Natl Acad Sci U S A*. 1987; 84: 6919-6923.
- 9 Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*. 2003; 34: 154-156.
- 10 Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin/kexin 9 (PCSK9) gene in cholesterol metabolism and disease. *Hum Mutat*. 2009; 30: 520-529.
- 11 Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. *Clin Gen*. 2008; 78: 1-13.
- 12 Chmara M, Wasag B, Zuk J, et al. Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. *J Appl Genet*. 2010; 51: 95-106.
- 13 Huang CC, Fornage M, Lloyd-Jones DM, et al. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. *Circ Cardiovasc Genet*. 2009; 2: 354-361.
- 14 Austin MA, Hutter CM, Zimmern RL, Humphries S. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol*. 2004; 160: 421-429.
- 15 Vermissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. *BMJ*. 2008; 337: a2423.
- 16 Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. *Atherosclerosis*. 2010; 209: 189-194.
- 17 Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J*. 2008; 29: 2625-2633.
- 18 Ito MK, McGowan MP, Moriarty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hyperlipidemias in adult patients. recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*. 2011; 5 (3 Suppl): S38-S45.
- 19 Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. *Community Genet*. 2008; 11: 26-35.
- 20 Hegele RA. Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. *Genome*. 2006; 49: 1343-1350.
- 21 Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*. 2011; 5 (3 Suppl): S1-S8.
- 22 Nicholls P, Young I, Lyttle K, Graham C. Screening for familial hypercholesterolaemia. Early identification and treatment of patients is important. *BMJ*. 2001; 322: 1062.
- 23 Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. *Am J Cardiol*. 2008; 102: 1187-1193.
- 24 Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. *Curr Opin Lipidol*. 2010; 21: 366-371.
- 25 Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. *J Clin Lipidol*. 2010; 4: 338-341.
- 26 Kusters DM, Homsma SJ, Hutten BA, et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. *Neth J Med*. 2010; 68: 299-303.
- 27 Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. *N Engl J Med*. 2012; 366: 1108-1118.
- 28 Giugliano RP, Desai NR, Kohli P, et al.; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. *Lancet*. 2012; 380: 2007-2017.
- 29 Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*. 2012; 126: 2408-2417.
- 30 McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236 553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. *J Am Coll Cardiol*. 2012; 59: 2344-2353.
- 31 Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236 553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet*. 2012; 380: 29-36.
- 32 Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. *JAMA*. 2012; 308: 2497-2506.